These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1568 related articles for article (PubMed ID: 24612209)

  • 1. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.
    Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E
    Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
    Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
    Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
    Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
    Teisner AS; Ainsworth MA; Brynskov J
    Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
    García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
    J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab in active ulcerative colitis: a "real-life" observational study.
    ; Armuzzi A; Biancone L; Daperno M; Coli A; Pugliese D; Annese V; Aratari A; Ardizzone S; Balestrieri P; Bossa F; Cappello M; Castiglione F; Cicala M; Danese S; D'Incà R; Dulbecco P; Feliciangeli G; Fries W; Genise S; Gionchetti P; Gozzi S; Kohn A; Lorenzetti R; Milla M; Onali S; Orlando A; Papparella LG; Renna S; Ricci C; Rizzello F; Sostegni R; Guidi L; Papi C
    Dig Liver Dis; 2013 Sep; 45(9):738-43. PubMed ID: 23683530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.